查看文章

Post-transplant lymphoproliferative disorders (PTLDs) were first described in 1968. The incidence of PTLD varies depending on the organ transplanted, being the highest following multi-organ and intestinal transplant (≤ 20%), followed by lung (3–10%), cardiac (2–8%), liver (1–5.5%), pancreatic (0.5–5%), and kidney (0.8–2.5%) transplant [Citation 1, Citation 2]. T-cell PTLDs comprise only 2–15% of all PTLDs and often develop late after transplantation, developing at a median of 9 years post-solid organ transplant [Citation 3–6]. Recent survey of the literature reveals over 150 cases of PTLDs of T/NK-cell lineage [Citation 3, Citation 4, Citation 7]. These particular types of PTLD are highly heterogeneous and aggressive diseases, which are generally Epstein-Barr virus (EBV)-negative, with a predilection for extranodal sites. They are associated with a poor prognosis, similar to the non-PTLD peripheral T-cell …